Isogenica announces leadership appointments
Isogenica has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong foundation for Isogenica’s future growth
Isogenica today announced that it has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong foundation for Isogenica’s future growth. William (Bill) Eldridge joins as Senior Director of Alliances and Edward McGowan joins in the newly created role of Senior Director of Antibody Discovery and Development. Both appointments are effective immediately.
Drs Eldridge and McGowan bring a wealth of biotherapeutic discovery and development experience to Isogenica. Bill was most recently Chief Scientific Officer at Cyclogenix where he led the discovery and development of scFv antibodies, Cyclotide scaffolds and VNAR single domains for half-life extension, specific oral availability and blood-brain barrier transfer. Bill was a senior researcher at Isogenica until 2009 and is a co-inventor of Isogenica’s CIS Display technology, which has been highly successful for the discovery of antibodies and peptides including Centyrins®. Edward McGowan joins Isogenica from Covance where he was Director of Biopharmaceutical Development. Prior to that Edward took roles of increasing seniority in biologics discovery and development at Ablynx, Ossianix and the International Aids Vaccine Initiative, building a deep knowledge of single domain antibodies in the process.
Drs Eldridge and McGowan join Edward Walker, newly promoted to Senior Director of Antibody Technologies, David Mead, Director of Business Development, and Chief Executive Emma Sceats in the company’s leadership team.
Commenting on these changes Björn Cochlovius, appointed as Isogenica’s Chairman in December 2019, said “The new leadership team will support delivery of Isogenica’s vision to become the pre-eminent single domain biotherapeutics company, improving patient outcomes via better targeting of chemotherapies and through the development of single domain bispecifics as off-the-shelf alternatives to CAR-T therapies.”
The company will be represented at the Biotech Showcase™ conference in San Francisco (13-15 January 2020) by Chairman Björn Cochlovius, Chief Executive Emma Sceats and David Mead, Business Development.
Further Information
Isogenica is developing LlamdA® (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years
Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
Contact
